title: Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre , East Melbourne, Victoria , Australia and University of Melbourne , Parkville, Victoria , Australia.
authors.forename: Chan Y
authors.initials: CY
authors.lastname: Cheah
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab